Biological considerations in locally advanced breast cancer treated with anthracycline-based neoadjuvant chemotherapy: thymidine labelling index is an independent indicator of clinical outcome

By Ozmen V.  

Breast Cancer Research and Treatment, Vol. 68, Iss. 2, 2001-07 ,pp. : 147-157

Springer Publishing Company

Access to resources Recommend Favorite

TOP2A amplification in breast cancer is a predictive marker of anthracycline-based neoadjuvant chemotherapy efficacy

By Wang Jiayu  

Breast Cancer Research and Treatment, Vol. 135, Iss. 2, 2012-09 ,pp. : 531-537

Springer Publishing Company

Access to resources Recommend Favorite

Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer

By Chen Xiaosong   Ye Guolin   Zhang Chenfang   Li Xinzheng   Chen Yiding   Xie Xiaohong   Zheng Hong   Cao Yali   Wu Kejin   Ni Duo   Tang Jinhai   Wei Ziguo   Shen Kunwei  

Breast Cancer Research and Treatment, Vol. 142, Iss. 3, 2013-12 ,pp. : 549-558

Springer Publishing Company

Access to resources Recommend Favorite

Results of two randomized trials evaluating adjuvant anthracycline-based chemotherapy in 1 146 patients with early breast cancer

By Arriagada Rodrigo   Spielmann Marc   Koscielny Serge   Le Chevalier Thierry   Delozier Thierry   Rémé-Saumon Monique   Ducourtieux Muriel   Tursz Thomas   Hill Catherine  

Acta Oncologica, Vol. 44, Iss. 5, 2005-07 ,pp. : 458-466

Informa Healthcare

Access to resources Recommend Favorite

Mortality, leukemic risk, and cardiovascular toxicity of adjuvant anthracycline and taxane chemotherapy in breast cancer: a meta-analysis

By Petrelli Fausto  

Breast Cancer Research and Treatment, Vol. 135, Iss. 2, 2012-09 ,pp. : 335-346

Springer Publishing Company

Access to resources Recommend Favorite